Skip to main content
Midas Edge

Akebia Therapeutics, Inc.

For the period ended Mar 31, 2026. Filed May 7, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 7, 2026

AKBA$0.54+1.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders' Equity (Deficit

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income · AccumulatedDeficit · Total Stockholders'(Deficit)
(dollars in thousands) · Shares · Amount
Balance at December 31, 2024224,848,992$2$1,629,167$6$(1,678,360)$(49,185)
Issuance of common stock, net of issuance costs34,437,364—64,907——64,907
Proceeds from sale of stock under employee stock purchase plan93,362—78——78
Exercise of options604,325—482——482
Stock-based compensation expense——2,187——2,187
Restricted stock unit vesting1,660,547—————
Net income————6,1126,112
Balance at March 31, 2025261,644,590$2$1,696,821$6$(1,672,248)$24,581
Common Stock · Additional Paid-InCapital · Accumulated Other Comprehensive Income · AccumulatedDeficit · Total Stockholders'Equity
(dollars in thousands)SharesAmount
Balance at December 31, 2025265,424,818$2$1,716,307$6$(1,683,705)$32,610
Proceeds from sale of stock under employee stock purchase plan96,347—131——131
Exercise of options28,424—20——20
Stock-based compensation expense——3,668——3,668
Restricted stock unit vesting2,348,826—————
Net loss————(9,054)(9,054)
Balance at March 31, 2026267,898,415$2$1,720,126$6$(1,692,759)$27,375
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.